Pharma Giants Race to Develop Heart Attack Prevention Drugs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy NVS?
Source: CNBC
- Heart Attack Prevention Drug Development: Novartis, Amgen, and Eli Lilly are conducting late-stage trials to test whether drugs that lower Lp(a) cholesterol levels can effectively prevent heart attacks, with potential annual sales reaching $5.6 billion by 2032 if successful.
- Importance of Clinical Trials: Novartis' pelacarsen has shown over 80% efficacy in reducing Lp(a) levels; however, delays in trial results have raised market concerns about its potential impact, particularly among patients with cardiovascular disease.
- Market Potential and Challenges: Despite the significant market potential for Lp(a) drugs, less than 1% of adults in the U.S. have been tested for Lp(a), and physician reluctance to screen may hinder drug adoption and market acceptance.
- Future Outlook: The results from Novartis' trials will provide direction on the clinical efficacy of Lp(a)-targeting drugs, and if successful, could open a new class of medications to meet the needs of high-risk patients while promoting wider adoption of Lp(a) testing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVS
Wall Street analysts forecast NVS stock price to fall
6 Analyst Rating
1 Buy
4 Hold
1 Sell
Hold
Current: 145.500
Low
112.00
Averages
127.75
High
143.00
Current: 145.500
Low
112.00
Averages
127.75
High
143.00
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novartis Projects 8% Sales Growth for 2025 Amid Patent Challenges
- Sales Growth Projection: Novartis anticipates an 8% sales growth for 2025 despite facing historic patent cliffs, indicating confidence in its new product development and market expansion strategies, which may attract investor interest in its long-term growth potential.
- Patent Challenges: The company commits to driving growth amidst patent expirations, reflecting its ongoing investment in R&D and innovation aimed at mitigating the revenue impact of patent losses.
- Strategic Partnership: Novartis has entered into a collaboration with Synnovation, enhancing its competitiveness in the biopharmaceutical sector, which is expected to support future product line expansions and market share increases.
- EU Application Withdrawal: The withdrawal of Novartis's application to expand the Pluvicto label for prostate cancer in the EU may affect short-term sales expectations in that market, but it also demonstrates the company's cautious approach to regulatory compliance.
See More
Novartis Q1 Earnings Announcement Scheduled
- Earnings Release Date: Novartis is set to announce its Q1 earnings on April 28 before market open, with consensus EPS estimate at $2.07 and revenue expected at $13.48 billion, indicating significant market anticipation for the company's performance.
- Historical Performance Review: Over the past two years, Novartis has beaten EPS estimates 75% of the time and revenue estimates 63% of the time, showcasing a stable performance that bolsters investor confidence amid market scrutiny.
- Expectation Revisions: In the last three months, there have been no upward revisions for EPS estimates and one downward revision, while revenue estimates also saw no upward revisions and two downward adjustments, reflecting a cautious market outlook on Novartis's future growth.
- Market Reaction Analysis: Despite facing 'historic' patent cliffs, analysts remain optimistic about Novartis's growth potential, suggesting that the company’s innovation and market strategies could lead to sustained growth opportunities.
See More
AstraZeneca and GSK Q1 Earnings Beat Expectations
- AstraZeneca Earnings Surprise: AstraZeneca reported a core earnings per share of $2.58 for Q1, surpassing the expected $2.53, indicating strong performance in a competitive pharmaceutical market, which is likely to boost investor confidence further.
- GSK's Strong Performance: GSK's core EPS was £0.47 ($0.63), exceeding the forecast of £0.43, reflecting success in new drug development and market penetration, which may attract more investor interest in its growth potential.
- Market Environment Challenges: As President Trump pushes for lower drug prices in the U.S., pharma CEOs warn that Europe could see fewer new drug launches unless competitiveness issues are addressed, potentially impacting AstraZeneca and GSK's long-term strategic plans.
- Revenue Growth Momentum: AstraZeneca's Q1 revenue reached $15.3 billion, an 8% year-on-year increase, beating expectations of $14.9 billion, indicating a strong start towards its goal of $80 billion in revenue by 2030, while GSK also reported revenue of £7.63 billion, up 5%.
See More
UAE's OPEC Exit Sends Shockwaves Through Markets
- UAE Exits OPEC: The UAE announced its exit from OPEC effective May 1, with the Energy Minister stating a desire for more freedom to achieve a capacity goal of 5 million barrels per day by 2027, a move that could prompt other members to follow suit and weaken OPEC's influence.
- Muted Market Reaction: Despite the significant news of the UAE's departure, oil prices remain stable, and both Asian stocks and European futures show relatively muted performance, indicating a cautious market response to the announcement.
- Strong European Banking Performance: UBS reported a first-quarter profit of $3 billion, exceeding expectations, while Santander's profit surged by 60%, and Deutsche Bank also beat bottom-line forecasts, highlighting a robust recovery in the European banking sector.
- Airline Industry Crisis Warning: Ryanair's CEO warned that European airlines could face bankruptcy if jet fuel prices do not decline, reflecting the industry's concerns over rising operational costs.
See More
Novartis Reports Weaker-Than-Expected Q1 Results Amid Generic Competition
- Sales Decline: Novartis reported Q1 net sales of $13.1 billion, a 1% year-over-year decline and a 5% drop in constant currency, primarily due to 14 percentage points of generic competition offsetting 13 percentage points of volume growth, indicating significant market pressure.
- Core Profit Drop: Core operating profit fell to $4.9 billion, down 12% year-over-year and below the $5.18 billion forecast by analysts, reflecting the negative impact of declining net sales and increased R&D investments on profitability.
- Patent Cliff Challenge: Facing the steepest patent cliff in its history, Novartis saw a 42% drop in sales of its key drug Entresto, posing a significant revenue threat, although demand for newer therapies like Kisqali and Pluvicto surged by 59% and 73%, respectively, providing some support for future growth.
- Full-Year Outlook: Despite challenges, Novartis remains on track for low single-digit sales growth and a low single-digit decline in core operating income for 2026, with the CEO expressing optimism about multiple drug readouts in the second half that could enhance mid- to long-term growth prospects.
See More
Novartis CEO Warns of Drug Pricing Policy Impact
- Drug Pricing Policy Warning: Novartis CEO Vas Narasimhan warned that the U.S. Most Favored Nation (MFN) drug pricing policy poses a 'very difficult situation' for both drugmakers and patients, with significant long-term implications expected to manifest in the next 18 months.
- Market Access Delay Risk: He emphasized that Novartis is focused on urging European and Japanese governments to quickly change how they reward innovation, as failure to do so could delay the entry of novel medicines into these markets, denying patients access to essential drugs.
- Limited Sales Impact: Narasimhan noted that the MFN policy currently affects only about 5-10% of Novartis's sales in the Medicaid segment, and while there are 'good early discussions' with European governments, insufficient action has been taken to address the impending challenges.
- Concerns Over German Policy: He expressed concern over Germany's recent proposal to cut drug costs, suggesting that such measures could lead the market in the wrong direction, and stressed that governments must take the MFN policy's implications seriously.
See More
Novartis Projects 8% Sales Growth for 2025 Amid Patent Challenges
- Sales Growth Projection: Novartis anticipates an 8% sales growth for 2025 despite facing historic patent cliffs, indicating confidence in its new product development and market expansion strategies, which may attract investor interest in its long-term growth potential.
- Patent Challenges: The company commits to driving growth amidst patent expirations, reflecting its ongoing investment in R&D and innovation aimed at mitigating the revenue impact of patent losses.
- Strategic Partnership: Novartis has entered into a collaboration with Synnovation, enhancing its competitiveness in the biopharmaceutical sector, which is expected to support future product line expansions and market share increases.
- EU Application Withdrawal: The withdrawal of Novartis's application to expand the Pluvicto label for prostate cancer in the EU may affect short-term sales expectations in that market, but it also demonstrates the company's cautious approach to regulatory compliance.
See More
Novartis Q1 Earnings Announcement Scheduled
- Earnings Release Date: Novartis is set to announce its Q1 earnings on April 28 before market open, with consensus EPS estimate at $2.07 and revenue expected at $13.48 billion, indicating significant market anticipation for the company's performance.
- Historical Performance Review: Over the past two years, Novartis has beaten EPS estimates 75% of the time and revenue estimates 63% of the time, showcasing a stable performance that bolsters investor confidence amid market scrutiny.
- Expectation Revisions: In the last three months, there have been no upward revisions for EPS estimates and one downward revision, while revenue estimates also saw no upward revisions and two downward adjustments, reflecting a cautious market outlook on Novartis's future growth.
- Market Reaction Analysis: Despite facing 'historic' patent cliffs, analysts remain optimistic about Novartis's growth potential, suggesting that the company’s innovation and market strategies could lead to sustained growth opportunities.
See More
AstraZeneca and GSK Q1 Earnings Beat Expectations
- AstraZeneca Earnings Surprise: AstraZeneca reported a core earnings per share of $2.58 for Q1, surpassing the expected $2.53, indicating strong performance in a competitive pharmaceutical market, which is likely to boost investor confidence further.
- GSK's Strong Performance: GSK's core EPS was £0.47 ($0.63), exceeding the forecast of £0.43, reflecting success in new drug development and market penetration, which may attract more investor interest in its growth potential.
- Market Environment Challenges: As President Trump pushes for lower drug prices in the U.S., pharma CEOs warn that Europe could see fewer new drug launches unless competitiveness issues are addressed, potentially impacting AstraZeneca and GSK's long-term strategic plans.
- Revenue Growth Momentum: AstraZeneca's Q1 revenue reached $15.3 billion, an 8% year-on-year increase, beating expectations of $14.9 billion, indicating a strong start towards its goal of $80 billion in revenue by 2030, while GSK also reported revenue of £7.63 billion, up 5%.
See More
UAE's OPEC Exit Sends Shockwaves Through Markets
- UAE Exits OPEC: The UAE announced its exit from OPEC effective May 1, with the Energy Minister stating a desire for more freedom to achieve a capacity goal of 5 million barrels per day by 2027, a move that could prompt other members to follow suit and weaken OPEC's influence.
- Muted Market Reaction: Despite the significant news of the UAE's departure, oil prices remain stable, and both Asian stocks and European futures show relatively muted performance, indicating a cautious market response to the announcement.
- Strong European Banking Performance: UBS reported a first-quarter profit of $3 billion, exceeding expectations, while Santander's profit surged by 60%, and Deutsche Bank also beat bottom-line forecasts, highlighting a robust recovery in the European banking sector.
- Airline Industry Crisis Warning: Ryanair's CEO warned that European airlines could face bankruptcy if jet fuel prices do not decline, reflecting the industry's concerns over rising operational costs.
See More
Novartis Reports Weaker-Than-Expected Q1 Results Amid Generic Competition
- Sales Decline: Novartis reported Q1 net sales of $13.1 billion, a 1% year-over-year decline and a 5% drop in constant currency, primarily due to 14 percentage points of generic competition offsetting 13 percentage points of volume growth, indicating significant market pressure.
- Core Profit Drop: Core operating profit fell to $4.9 billion, down 12% year-over-year and below the $5.18 billion forecast by analysts, reflecting the negative impact of declining net sales and increased R&D investments on profitability.
- Patent Cliff Challenge: Facing the steepest patent cliff in its history, Novartis saw a 42% drop in sales of its key drug Entresto, posing a significant revenue threat, although demand for newer therapies like Kisqali and Pluvicto surged by 59% and 73%, respectively, providing some support for future growth.
- Full-Year Outlook: Despite challenges, Novartis remains on track for low single-digit sales growth and a low single-digit decline in core operating income for 2026, with the CEO expressing optimism about multiple drug readouts in the second half that could enhance mid- to long-term growth prospects.
See More
Novartis CEO Warns of Drug Pricing Policy Impact
- Drug Pricing Policy Warning: Novartis CEO Vas Narasimhan warned that the U.S. Most Favored Nation (MFN) drug pricing policy poses a 'very difficult situation' for both drugmakers and patients, with significant long-term implications expected to manifest in the next 18 months.
- Market Access Delay Risk: He emphasized that Novartis is focused on urging European and Japanese governments to quickly change how they reward innovation, as failure to do so could delay the entry of novel medicines into these markets, denying patients access to essential drugs.
- Limited Sales Impact: Narasimhan noted that the MFN policy currently affects only about 5-10% of Novartis's sales in the Medicaid segment, and while there are 'good early discussions' with European governments, insufficient action has been taken to address the impending challenges.
- Concerns Over German Policy: He expressed concern over Germany's recent proposal to cut drug costs, suggesting that such measures could lead the market in the wrong direction, and stressed that governments must take the MFN policy's implications seriously.
See More
